News

US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ (“PMX”) for the Treatment of Endotoxemic Septic Shock

Breakthrough designation expected to help accelerate regulatory reviewTORONTO, July 11, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the…

2 years ago

EyePoint Pharmaceuticals to Host Investor Day on July 18, 2022

- Guest speakers Carl Regillo, M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University and Charles C. Wykoff, M.D., Ph.D., Director…

2 years ago

Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA

--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical…

2 years ago

Opus Genetics to Present at OIS Retina Innovation Summit 2022

RESEARCH TRIANGLE PARK, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for…

2 years ago

Jushi Announces Grand Reopening of Beyond Hello™ Palm Springs

Jushi Holdings Inc. Announces Grand Reopening of Palm Springs Dispensary Jushi Holdings Inc. to host the grand reopening of its…

2 years ago

Quipt Surpasses 200,000 Active Patients Adding Approximately $7 Million in Annualized Revenues, and Anticipated $1.4 Million of Adjusted EBITDA Post Integration

Acquisition of Hometown Medical, LLC Significantly Enhances Presence in MississippiCINCINNATI, July 11, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp.…

2 years ago

Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that…

2 years ago

Axogen, Inc. Appoints William Burke to Board of Directors

Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of DirectorsALACHUA, Fla. and TAMPA, Fla.,…

2 years ago

EyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors

WATERTOWN, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and…

2 years ago

MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

MW005 Shown to Be Safe and Well-ToleratedTarget Lesions Clearance Data Provides Clinical Efficacy Proof-of-Concept YAVNE, Israel, July 11, 2022 (GLOBE…

2 years ago